ENO3 and hepatocellular carcinoma: Together, these data strongly suggested that ENO3 was downregulated in HCC, and the low expression was related to undesirable clinical outcomes in the HCC patients, which provided prima facie evidence that ENO3 might be pivotal for HCC.